
Shares of Swiss biotech MoonLake Immunotherapeutics MLTX.O rise 14.8% to $47.25
Merck MRK.N has held talks to buy MLTX for more than $3 billion, the Financial Times reported on Monday, citing people familiar with the matter
Merck had submitted a nonbinding offer for MoonLake earlier this year - report
MRK's initial approach was rejected, but discussions can potentially resume, the report says
Including session moves, MLTX down 12.6% YTD